

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims

1-12. (Canceled).

13. (Currently Amended) A method of treating alcohol addiction, a bipolar or manic condition, bulimia, chronic fatigue syndrome, narcolepsy, premenstrual syndrome, or neuropathic pain which comprises administering to a patient having said disorder a therapeutically effective amount of optically pure ~~(S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol~~ (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof.

14-60. (Canceled).

61. (Currently amended) The method of claim 13 wherein the effective amount of optically pure ~~(S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol~~ (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is from about 1 mg to about 750 mg per day.

62. (Currently amended) The method of claim 13 wherein the effective amount of optically pure ~~(S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol~~ (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is from about 5 mg to about 700 mg per day.

63. (Currently amended) The method of claim 13 wherein the effective amount of optically pure ~~(S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol~~ (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is from about 10 mg to about 650 mg per day.

64. (Currently amended) The method of claim 13 wherein optically pure ~~(S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol~~ (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-

morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered orally, transdermally, and mucosally.

65. (Currently amended) The method of claim 64 wherein optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered orally.

66. (Currently amended) The method of claim 64 wherein optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered transdermally.

67. (Currently amended) The method of claim 64 wherein optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, is administered mucosally.

68. (Withdrawn) The method of claim 13 wherein alcohol addiction is treated.

69. (Canceled).

70. (Previously presented) The method of claim 13 wherein a bipolar or manic condition is treated.

71. (Withdrawn) The method of claim 13 wherein bulimia is treated.

72. (Withdrawn) The method of claim 13 wherein chronic fatigue syndrome is treated.

73. (Withdrawn) The method of claim 13 wherein narcolepsy is treated.

74. (Canceled).

75. (Withdrawn) The method of claim 13 wherein premenstrual syndrome is treated.

76. (Currently amended) The method of claim 13 wherein the optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol is in the form of an acceptable salt.

77. (Withdrawn) The method of claim 13 wherein the optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol is in the form of a solvate.

78. (Canceled).

79. (Withdrawn) The method of claim 13, wherein neuropathic pain is treated.